Merck & Co Inc (NYSE:MRK) unveiled results from a Phase 2b/3 trial (MK-1654-004) evaluating clesrovimab, the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season. The results and interim findings from the ongoing Phase 3 trial (MK-1654-007) of clesrovimab were presented during IDWeek 2024. Results from the Phase 2b/3 pivotal trial evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants (birth to 1 year of age) met all prespecified endpoints, with …